Summary:
- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2020 financial results and operational highlights in a conference call on November 5, 2020 at 8 a.m. ET. To join the call: * U.S. callers should dial 1-877-317-6789 and international callers should dial 1-412-317-6789, approximately five mi...
Upgrades * According to UBS, the prior rating for United Parcel Service Inc (NYSE: UPS) was changed from Neutral to Buy. In the second quarter, United Parcel Service showed an EPS of $2.13, compared to $1.96 from the year-ago quarter. The current stock performance of United Parcel Service shows a 52-week-high of 178.01 and a 52-week-low of 82.0. Moreover, at the end of the last trading period, the closing price was at $167.90. * According to JP Morgan, the prior rating for NCR Corp (NYSE: NCR...
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR On track to dose first patient by year-end with a systemically delivered CRISPR/Cas9-based therapyCAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate its Phase 1 study, which will evaluate NTLA-2001 for the treatmen...
CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr. Doudna shared the award with her research collaborator, Dr. Emmanuelle Charpentier. This is the first time two women scientists have jointly won a Nobel Prize in Chemistry. Since the publication of the seminal 2012 Science paper, Dr. Doudn...
This year’s Nobel Prize for chemistry was awarded to the two discoverers of Crispr/Cas9, which has led to gene-editing treatments for inherited illnesses like sickle-cell anemia.
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has appointed John F. Crowley to its Board of Directors. Mr. Crowley is a well-established leader in biotech and pharmaceuticals and a visionary advocate for the advancement of treatments for people living with rare diseases. He joins Intellia’s board during a pivotal tran...